biogen idec

July 28, 2006

Russell Katz
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Neurology Products
5901-B Ammendale Road
Beltsville, MD 20705-1266

RE: IND 73,061: BG00012 (Dimethyl Fumarate): Multiple Sclerosis
End-of-Phase 2 Meeting (Type B) Briefing Package
Serial No.: 0006

Dear Dr. Katz,

Reference is made to the Type B meeting (End of Phase 2) scheduled on August 30, 2006 (from 15:00 to 16:30) for BG00012, which is being developed by Biogen Idec for the treatment of patients with relapsing-remitting multiple sclerosis (MS).

In anticipation of the meeting, Biogen Idec is submitting 9 copies of the meeting briefing document (9 desk copies on CD), in addition to an electronic copy.

The agenda, proposed meeting participants and sponsor questions are provided in Section 3 of the briefing document.

Should you have any questions regarding this request, please contact Tammy Sarnelli at (617) 679-3513 or myself.

Sincerely Yours,

[redacted]

Senior Vice President, Regulatory Affairs
Phone (617) 679-3783
Fax (617) 679-3170